The various FGFR2 mutations exhibited diverse responses to FGFR-selective small molecule kinase inhibitors in ICC cells, thereby highlighting the need to consider unique mutation profiles when devising targeted therapeutics. The gene discussed is FGFR2; the disease is intrahepatic cholangiocarcinoma.